MONMOUTH JUNCTION, N.J., March 3 /PRNewswire/ — MicroDose Technologies Inc. (MicroDose) today announced that it has entered into a global license agreement with Merck & Co., Inc., through an affiliate, for use of MicroDose’s proprietary dry powder inhaler (DPI) with Merck compounds. This agreement follows the successful completion of an exploratory study evaluating the MicroDose DPI technology.
Posts under ‘Uncategorized’
Innovata and MicroDose Regain Rights to Inhaled Insulin from Bristol-Myers Squibb
Nottingham, UK, December 7, 2005 – Innovata plc (LSE: IOV.L) today announced the restructuring of the agreement between QDose, its joint venture with MicroDose Technologies Inc. (MicroDose), and Bristol-Myers Squibb Company (NYSE: BMY) relating to fast acting inhaled insulin. Bristol-Myers Squibb has decided to reallocate resources dedicated to QDose to other pipeline priorities and has transferred to QDose all rights to the product.
3M Drug Delivery Systems and MicroDose Technologies, Inc. Team Up to Bring Advanced Electronic Dry Powder Inhaler Technology to Market Collaboration will Provide Fully Integrated Drug Delivery Solutions for the Pharmaceutical and Biotechnology Industries
St. Paul, MN — (Businesswire) — July 19, 2004 — 3M and MicroDose Technologies, Inc. a privately held drug delivery company based in Monmouth Junction, New Jersey, announced today that the two companies have entered into an exclusive co-development and joint marketing agreement.
Microdose Reports Success In First Clinical Trial For Inhaled Insulin Using Novel Microdose Device; Needle-Free Alternative For Diabetes Treatment
Monmouth Junction, NJ, USA, 4th December 2001— MicroDose Technologies Inc. ( MicroDose ), a leading drug delivery company, announced today the successful completion of a Phase I clinical study evaluating the pulmonary delivery of human insulin, being conducted with joint venture partner, Elan Corporation, plc ( Elan ).
Quadrant Healthcare PLC Joint Venture With Microdose Technologies to Exploit Pulmonary Delivery of Peptides and Proteins
Nottingham, UK – 30 November 1999 – Quadrant Healthcare plc (“Quadrant” or the “Company”), the UK drug delivery company, announced today that it has agreed to form a new joint venture company with MicroDose Technologies Inc (“MicroDose”), a US based drug delivery systems company, to develop and exploit the pulmonary delivery of peptides and proteins.